Skip to content

Paroxetine CR vs Escitalopram in Panic Disorder.

Efficacy of Paroxetine controlled release and Escitalopram in patients with Panic disorder : A Randomised Controlled Trial. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/09/057378
Enrollment
72
Registered
2023-09-11
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F410- Panic disorder [episodic paroxysmal anxiety]

Interventions

Intervention1: Escitalopram: Starting dose of Tablet Escitalopram is 10mg per day ,once daily, orally for 4 weeks and to be continued for 12 weeks if adequate clinical response at 4 weeks. (Adequate

Sponsors

Dr Sahil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1)Patients meeting the diagnostic criteria of panic disorder with or without agoraphobia as per DSM-5 2)Male or female patients in the age group of 18-65 years (both inclusive). 3)Patients willing to give written informed consent. 4)Symptom onset atleast 3 months prior to enrolment in study (in case of newly diagnosed patients) or off medication for atleast 3 months prior to enrolment in study (in already diagnosed patients of panic disorder). Patients with Panic Disorder Severity Scale Score = 8 on screening.

Exclusion criteria

Exclusion criteria: Exclusion Criteria: 1)Patients with Montgomery-Asberg Depression Rating Scale (MADRS) score = 20 and Generalized Anxiety Disorder Scale 7 (GAD-7) score = 10. 2)Pregnant women or nursing mothers. 3)Women planning to conceive. (in patient consent form it has been included that patient will not conceive for next 8 weeks) 4)Patient’s symptoms are associated with or attributable to an identifiable cause such as Hyperthyroidism, Asthma, Cardiovascular diseases (like angina, congestive heart failure etc ) or Substance use disorder. 5)Patients with known history of dyslipidemia. 6)Patients with diabetes mellitus, uncontrolled hypertension, heart block, bradycardia (pulse 7)History of acute myocardial infarction or stroke. 8)Patients having history suggestive of psychosis or dementia.

Design outcomes

Primary

MeasureTime frame
1. Severity of Panic attacks. 2. Frequency of panic attacks. 3. Percentage of patients free from full symptom panic attacks.Timepoint: 12 weeks

Secondary

MeasureTime frame
1. Percentage of Responders. 2. Need for rescue medication.Timepoint: 12 weeks

Countries

India

Contacts

Public ContactDr Manish Thakre

Government Medical College and Hospital, Nagpur

drmanishthakre@gmail.com9850977266

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026